Chest
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: European respiratory society (ERS) guidelines recommend to stratify patients with acute exacerbations of COPD (AECOPD) according to the presence or not of risk factors(RF) for Pseudomonas aeruginosa (PA). There is controversy regarding the need to empirically cover PA in clinical practice. Therefore a better understanding of the prevalence and RF for PA in hospitalized patients with AECOPD is critical in order to appropriately adhere to clinical practice guidelines. Aim: 1) Determine the prevalence of PA pathogens and PA risk RF in hospitalized patients with AECOPD; and 2) Assess the association of PA isolation and PA RF among hospitalized patients with AECOPD. ⋯ The following authors have nothing to disclose: Pedro Marcos, Pilar Sanjuan, Santiago Rodriguez-Segade, Natalia Uribe-Giraldo, Marina Blanco-Aparicio, Isabel Otero, Jorge Ricoy, Hector Verea, Marcos RestrepoNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Patients with Idiopathic Pulmonary Fibrosis (IFP) demonstrate widely variable clinical courses and survival. Thus, predicting prognosis in patients with IPF is a challenge for clinicians. Multidimensional GAP (gender, age and 2 lung physiology variables [FVC and DLCO]) index and staging system was developed to predict mortality in IPF. The purpose of this study is to use GAP multidimensional index in IPF patients observed in recent years in our Interstitial Lung Diseases (ILD) outpatient clinic and understand if our results go in line with the published data. ⋯ The following authors have nothing to disclose: Margarida Redondo, Natalia Melo, Diogo Costa, Patricia Mota, Antonio MoraisNo Product/Research Disclosure Information.
-
DVT/PE/Pulmonary HypertensionSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: The goal of this study was to determine if biomarkers of collagen metabolism in idiopathic, hereditary and anorexigen associated pulmonary arterial hypertension (PAH) identify patients with worse disease and higher risk of death. ⋯ Zeenat Safdar: Consultant fee, speaker bureau, advisory committee, etc.: Acetelion, United Therapeutics, Gilead sciences and Bayer pharmaceuticals Adaani Frost: Consultant fee, speaker bureau, advisory committee, etc.: Gilead sciences, Bayer, United therapeutics, Acetlion, pfizer The following authors have nothing to disclose: Emilio Tameez, Mark EntmanNo Product/Research Disclosure Information.
-
Slide PresentationPRESENTED ON: Monday, March 24, 2014 at 10:45 AM - 11:45 AMPURPOSE: Recently, the CAT is recommended as a promising tool for assessing the impact of COPD on the indivudual patient. Although it was known that COPD patients have a high frequency of comorbidities, little known about the contribution of these comorbidities to CAT score. We aimed to assess the impact of comorbidities on disease specific health status as assessed by CAT in patients with stable COPD. ⋯ The following authors have nothing to disclose: Sibel Atis Nayci, Eylem Sercan Özgür, Cengiz Özge, Yasin Duman, Ahmet IlvanNo Product/Research Disclosure Information.
-
ILD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Several clinical and case studies show that short-term treatment with anti-fungal medication improved the clinical status of the disease. To further explore this, a study was undertaken where treated patients were followed till healing of the disease. ⋯ The following authors have nothing to disclose: Marjeta Tercelj, Barbara Salobir, Mirjana Zupancic, Ragnar RylanderNo Product/Research Disclosure Information.